+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Orphan Drugs Market by Disease Type, Product Type, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5674387
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Orphan Drugs Market grew from USD 191.86 billion in 2023 to USD 216.80 billion in 2024. It is expected to continue growing at a CAGR of 13.39%, reaching USD 462.45 billion by 2030.

Orphan drugs, designed to treat rare diseases affecting a small percentage of the population, present a unique scope defined by unmet medical needs and specialized patient engagement. The necessity for these drugs is paramount as they address conditions that often lack alternative treatments, holding significant potential to improve patient outcomes and quality of life. They are primarily applied in the treatment of rare genetic disorders, rare cancers, and debilitating chronic conditions. The end-use scope spans hospitals, specialty clinics, and research institutes focused on rare diseases, driving demand for personalized medicine approaches. Market growth is heavily influenced by advancements in biotechnology, regulatory incentives like the Orphan Drug Act in the U.S., and increasing prevalence of rare diseases globally. The latest opportunities lie in leveraging personalized medicine, gene therapy advancements, and global pharmaceutical partnerships. Companies can capitalize on these by investing in R&D collaborations, expanding clinical trials internationally, and ensuring agile regulatory approaches. However, limitations include high development costs, complex regulatory landscapes, and challenges in securing sufficient return on investment given the small patient populations. Market access difficulties in less developed regions and resistance from payers due to high drug pricing further compound these challenges. Innovation is best directed towards novel therapeutic platforms such as CRISPR and RNA-based treatments, alongside exploring new drug discovery technologies that enhance efficacy and safety profiles. Understanding patient-community networks and data analytics can also offer breakthroughs by better aligning therapeutic offerings with patient needs. The market for orphan drugs is characterized by its rapid growth, high investment risks, and potential for substantial rewards. Companies venturing into this field should maintain agility in their strategies, foster innovation through cross-sector collaboration, and maintain a patient-centric approach to effectively address this growing but challenging market.

Understanding Market Dynamics in the Orphan Drugs Market

The Orphan Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Surge in prevalence of rare diseases and increasing healthcare expenditure
    • Favorable government and economic incentives for the development of drugs for rare diseases
    • Availability of exclusivity for orphan drugs
  • Market Restraints
    • High cost associated with orphan drugs
  • Market Opportunities
    • Increasing R&D initiatives and development of novel products
    • Regulatory incentives for the development of orphan drugs in emerging countries
  • Market Challenges
    • Side effects associated with orphan drugs

Exploring Porter’s Five Forces for the Orphan Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Orphan Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Orphan Drugs Market

External macro-environmental factors deeply influence the performance of the Orphan Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Orphan Drugs Market

The Orphan Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Orphan Drugs Market

The Orphan Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Orphan Drugs Market

The Orphan Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Orphan Drugs Market, highlighting leading vendors and their innovative profiles. These include Alexion Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Belite Bio Inc, Biogen Inc., Dynacure SA, Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., MeiraGTx Limited, Novartis AG, Pfizer Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Orphan Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Disease Type
    • Gastrointestinal
    • Hematology
    • Infectious Diseases
    • Neurology
    • Oncology
    • Pulmonary
  • Product Type
    • Biologic
    • Non-Biologic
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Surge in prevalence of rare diseases and increasing healthcare expenditure
5.1.1.2. Favorable government and economic incentives for the development of drugs for rare diseases
5.1.1.3. Availability of exclusivity for orphan drugs
5.1.2. Restraints
5.1.2.1. High cost associated with orphan drugs
5.1.3. Opportunities
5.1.3.1. Increasing R&D initiatives and development of novel products
5.1.3.2. Regulatory incentives for the development of orphan drugs in emerging countries
5.1.4. Challenges
5.1.4.1. Side effects associated with orphan drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Orphan Drugs Market, by Disease Type
6.1. Introduction
6.2. Gastrointestinal
6.3. Hematology
6.4. Infectious Diseases
6.5. Neurology
6.6. Oncology
6.7. Pulmonary
7. Orphan Drugs Market, by Product Type
7.1. Introduction
7.2. Biologic
7.3. Non-Biologic
8. Orphan Drugs Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Retail Pharmacies
8.4. Specialty Pharmacies
9. Americas Orphan Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Orphan Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Orphan Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ORPHAN DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ORPHAN DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ORPHAN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ORPHAN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. ORPHAN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ORPHAN DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ORPHAN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ORPHAN DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ORPHAN DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PULMONARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NON-BIOLOGIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ORPHAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. CANADA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 32. CANADA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 33. CANADA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. MEXICO ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 35. MEXICO ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 36. MEXICO ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. CHINA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 49. CHINA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 50. CHINA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. INDIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 52. INDIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. INDIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. JAPAN ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 58. JAPAN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. JAPAN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. THAILAND ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 76. THAILAND ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. THAILAND ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. DENMARK ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 86. DENMARK ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. DENMARK ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. EGYPT ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 89. EGYPT ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 90. EGYPT ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. FINLAND ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 92. FINLAND ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. FINLAND ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. FRANCE ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 95. FRANCE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 96. FRANCE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. GERMANY ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 98. GERMANY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 99. GERMANY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. ITALY ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 104. ITALY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 105. ITALY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. NORWAY ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 113. NORWAY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 114. NORWAY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. POLAND ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 116. POLAND ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 117. POLAND ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. QATAR ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 119. QATAR ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. QATAR ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SPAIN ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 131. SPAIN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 132. SPAIN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. TURKEY ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 140. TURKEY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. TURKEY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. ORPHAN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 149. ORPHAN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Orphan Drugs Market, which are profiled in this report, include:
  • Alexion Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Belite Bio Inc
  • Biogen Inc.
  • Dynacure SA
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • MeiraGTx Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

Methodology

Loading
LOADING...

Table Information